In this segment, Dr. Gregory Vidal outlines what a typical first-line treatment plan looks like for patients with ER-positive ...

Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co ...

The phase 3 study, known as Neo-Healer or KN026–004, was an open-label, multicenter trial that randomly assigned ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

New data confirm similar response rates with fewer toxicities when carboplatin is dropped from standard neoadjuvant therapy in early HER2-positive breast cancer.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated ...

L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms ...

Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study ...

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...

Enhertu approved in Japan as first tumour agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumours: Tokyo Tuesday, March 24, 202 ...

Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Daiichi Sankyo announces Enhertu now available in Japan as first ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer: Tokyo Wednesday, March 25, ...